Bristol-Myers Squibb company profile
Company profile
Bristol-Myers Squibb has 32,500 employees and is headquartered in Princeton, United States.
Doctors and patients treated for cancer, blood disorders, immune diseases, heart conditions and neurological illnesses are the core of the business of Bristol-Myers Squibb Company, which discovers, develops, manufactures and sells biopharmaceutical drugs worldwide. Key brands include Opdivo, Eliquis, Revlimid, Breyanzi and Zeposia, with products such as Cobenfy for schizophrenia and Camzyos for obstructive heart disease. Sales reach customers through a broad network of intermediaries and care providers, and the United States accounts for 69.1% of revenue, with 28.7% from other countries and 2.3% from other regions. The company was founded in 1887 and was formerly known as Bristol-Myers Company.
In the fiscal year ended December 2025, revenue reached 48.2 billion dollars, down 0.2% from the prior year, and net income was 7.1 billion dollars. The company employed 32,500 people and is headquartered in Princeton, New Jersey.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Headquarters
- Route 206 & Province Line Road, 08543, Princeton
- Employees
- 32,500
- Chief executive
- Christopher Boerner
- Founded
- 1887
- Fiscal year
- January - December
- Listing
- BMY · NYSE
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US1101221083
- Website
- bms.com
Bristol-Myers Squibb and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Bristol-Myers SquibbBMY | United States | $125.4B | 32,500 | 32.4% | 13.6 |
| PfizerPFE | United States | $164.5B | 75,000 | 29.1% | 41.2 |
| Gilead SciencesGILD | United States | $211.18B | 17,000 | 38.2% | — |
| AmgenAMGN | United States | $250.07B | 31,500 | 34.1% | 26.8 |
| Merck & Co.MRK | United States | $356.13B | 73,000 | 35.2% | 144.5 |
| BiogenBIIB | United States | $37.07B | 7,500 | 23.5% | 107.2 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
